Thursday, May 1, 2014
Publication and contact
Non-small cell lung cancer
Mouse studies suggest
blocking IL-17 could help treat or prevent inflammatory chronic obstructive
pulmonary disease (COPD)-associated NSCLC. In a mouse model of early NSCLC,
inoculation of COPD-generating lysates from Haemophilus influenza
increased tumor growth, which was associated with higher T helper type 17
(Th17) cell numbers, compared with no inoculation. In lysate-treated mice
with NSCLC, Il-17 knockout decreased tumor growth compared with Il-17f
knockout. Antibody-mediated depletion of Il-17-recruited myeloid cells
also decreased tumor growth compared with no alteration. Next steps include
investigating other reagents that could block Th17 cells such as IL-23-specific
antibodies or RAR-related
orphan receptor C thymus-specific isoform (RORg2; RORgT) inhibitors.
a humanized mAb against IL-17 receptor (IL17R;
Inc. and partners AstraZeneca
plc and Kyowa
Hakko Kirin Co. Ltd., is in Phase III testing to treat
psoriasis and Phase II trials to treat asthma, psoriatic arthritis and
At least eight other companies have compounds that block IL-17 signaling in
Phase II or earlier development to treat various autoimmune and inflammatory
Published online May 1, 2014
status not applicable
Chang, S.H. et al. Proc.
Natl. Acad. Sci. USA; published online
March 31, 2014;
Contact: Seyed Javad Moghaddam, The University of Texas MD
Anderson Cancer Center, Houston, Texas
Contact: Seon Hee Chang, same affiliation as above
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]